By Sahil Pandey And Joymala Bagchi
New Delhi, December 7 (ANI): Bharat Biotech on Monday applied for emergency use authorisation for its indigenously developed COVID-19 vaccine ‘Covaxin’ to Drugs Controller General of India (DCGI), officials said.
“Bharat Biotech has sought emergency use authorisation for its indigenously developed COVID-19 vaccine Covaxin from DCGI,” a senior government official told to ANI. Bharat Biotech is the third company which has applied for emergency use authorisation for its vaccine.
It is the second Indian company to apply for emergency use authorisation after the Serum Institute of India applied for such use for a vaccine developed by Oxford University and AstraZeneca.
Pfizer had applied for the emergency use authorisation to DCGI on December 6.
Pfizer India’s parent company Pfizer has already got emergency-use clearance in the United Kingdom and Bahrain.
India Tribune, as an English weekly newspaper, was launched in 1977 in Chicago by its publisher Prashant Shah with a lofty ideal to serve the Asian Indian community in the USA. Over the years, it has grown with all vigor, and now it is being published in three editions – Chicago, New York and Atlanta. India Tribune, a journal of its kind for the family in the USA, has been a household name for many Indians for over three decades with each issue commanding a readership of over 125,000.
